Neil Desai, MD

Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.